Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel

Background. The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D. Methods. Treatment consisted of D 30 mg/m(2) i.v. for four consecutive weekly administ...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Francini, Filippo, Pascucci, Alessandra, Francini, Edoardo, Bargagli, Gianluca, Conca, Raffaele, Licchetta, Antonella, Roviello, Giandomenico, Martellucci, Ignazio, Chiriacò, Giorgio, Miano, Salvatora Tindara, Marzocca, Giuseppe, Manganelli, Antonio, Ponchietti, Roberto, Savelli, Vinno, Petrioli, Roberto
Materialtyp: Artigo
Språk:Inglês
Publicerad: Hindawi Publishing Corporation 2011
Ämnen:
Clinical Study
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3200276/
https://ncbi.nlm.nih.gov/pubmed/22096653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2011/258689
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk